propranolol + etodolac

This is a **combination therapy** consisting of **propranolol**, a non-selective beta-adrenergic receptor antagonist (beta-blocker), and **etodolac**, a nonsteroidal anti-inflammatory drug (NSAID) with selective COX-2 inhibitory activity. **Propranolol** works by inhibiting the effects of catecholamines (stress hormones) on beta-adrenergic receptors, thereby reducing adrenergic signaling. **Etodolac** inhibits cyclooxygenase-2 (COX-2), reducing the synthesis of pro-inflammatory prostaglandins such as PGE-2. The combination aims to **suppress perioperative adrenergic and inflammatory responses**, which are hypothesized to contribute to cancer recurrence following surgery. The modality has been investigated primarily in the **perioperative setting for solid tumors**, especially pancreatic, breast, and colorectal cancers, with the goal of reducing postoperative recurrence and improving survival outcomes. The main mechanisms involve decreasing tumor-promoting inflammation and stress-mediated immune suppression. Initial safety and biomarker studies support the biological rationale and safety of this regimen, though large-scale efficacy data are pending[1][2][3][4][5][7][8].

Brand names

VT-122VT122VT 122

Other names

propranolol and etodolac combination